Invivyd completes enrollment in phase 3 COVID antibody trial
Tweet Send to a Friend
Invivyd Inc. (NASDAQ: IVVD) announced completion of enrollment in its DECLARATION clinical trial, a phase 3 study evaluating VYD2311, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


